# Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

> **NCT00118144** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Adenocarcinoma of the Lung
- Bronchoalveolar Cell Lung Cancer
- Non-small Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00118144
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118144, "Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00118144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*